Cargando…
Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome
Background. Tilted disc syndrome (TDS) is a congenital anomaly characterized by “tilting” of the optic disc tipycally associated with myopic astigmatism, visual field defect, inferior staphyloma, and retinal pigment epithelium atrophy. Associated complications such as macular serous neuroretinal det...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995910/ https://www.ncbi.nlm.nih.gov/pubmed/21151645 http://dx.doi.org/10.1155/2010/970580 |
_version_ | 1782193127289782272 |
---|---|
author | Milani, Paolo Pece, Alfredo Pierro, Luisa Seidenari, Patrizio Radice, Paolo Scialdone, Antonio |
author_facet | Milani, Paolo Pece, Alfredo Pierro, Luisa Seidenari, Patrizio Radice, Paolo Scialdone, Antonio |
author_sort | Milani, Paolo |
collection | PubMed |
description | Background. Tilted disc syndrome (TDS) is a congenital anomaly characterized by “tilting” of the optic disc tipycally associated with myopic astigmatism, visual field defect, inferior staphyloma, and retinal pigment epithelium atrophy. Associated complications such as macular serous neuroretinal detachment are well described; however, ideal therapy for such complication is unknown. Methods. One interventional case report is hereby described. A patient affected by macular serous neuroretinal detachment-complicated tilted disk syndrome underwent a complete ophthalmic examination. Optical coherence tomography and fluorescein angiography were taken at baseline and at scheduled visits. Two intravitreal treatments of bevacizumab (avastin, 1.25 mg/0.05 mL) were performed at monthly interval. Results. At scheduled visit, one month after the second injection, OCT depicted persistence of neuroretinal detachment. Best-corrected visual acuity remain stable as well as metamorphopsia and functional discomfort. Conclusion. Clinical evidence of this brief interventional case report indicates that one patient affected by recent serous macular detachment-complicated TDS did not benefit from 2 consecutive monthly intravitreal Avastin treatments. Best-corrected visual acuity remained stable over a total observation period of 6 months. |
format | Text |
id | pubmed-2995910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-29959102010-12-13 Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome Milani, Paolo Pece, Alfredo Pierro, Luisa Seidenari, Patrizio Radice, Paolo Scialdone, Antonio J Ophthalmol Case Report Background. Tilted disc syndrome (TDS) is a congenital anomaly characterized by “tilting” of the optic disc tipycally associated with myopic astigmatism, visual field defect, inferior staphyloma, and retinal pigment epithelium atrophy. Associated complications such as macular serous neuroretinal detachment are well described; however, ideal therapy for such complication is unknown. Methods. One interventional case report is hereby described. A patient affected by macular serous neuroretinal detachment-complicated tilted disk syndrome underwent a complete ophthalmic examination. Optical coherence tomography and fluorescein angiography were taken at baseline and at scheduled visits. Two intravitreal treatments of bevacizumab (avastin, 1.25 mg/0.05 mL) were performed at monthly interval. Results. At scheduled visit, one month after the second injection, OCT depicted persistence of neuroretinal detachment. Best-corrected visual acuity remain stable as well as metamorphopsia and functional discomfort. Conclusion. Clinical evidence of this brief interventional case report indicates that one patient affected by recent serous macular detachment-complicated TDS did not benefit from 2 consecutive monthly intravitreal Avastin treatments. Best-corrected visual acuity remained stable over a total observation period of 6 months. Hindawi Publishing Corporation 2010 2010-11-30 /pmc/articles/PMC2995910/ /pubmed/21151645 http://dx.doi.org/10.1155/2010/970580 Text en Copyright © 2010 Paolo Milani et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Milani, Paolo Pece, Alfredo Pierro, Luisa Seidenari, Patrizio Radice, Paolo Scialdone, Antonio Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome |
title | Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome |
title_full | Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome |
title_fullStr | Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome |
title_full_unstemmed | Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome |
title_short | Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome |
title_sort | bevacizumab for macular serous neuroretinal detachment in tilted disk syndrome |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995910/ https://www.ncbi.nlm.nih.gov/pubmed/21151645 http://dx.doi.org/10.1155/2010/970580 |
work_keys_str_mv | AT milanipaolo bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome AT pecealfredo bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome AT pierroluisa bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome AT seidenaripatrizio bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome AT radicepaolo bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome AT scialdoneantonio bevacizumabformacularserousneuroretinaldetachmentintilteddisksyndrome |